GZMA (Granzyme A)

Importantly, pro-inflammatory cytokines such as IL-6, IL-10, and IFN-γ remained at low levels, suggesting a favorable safety profile. These findings support the therapeutic potential of CD138-targeted BATs as a promising and potentially safer cellular immunotherapy for the treatment of MM.

We targeted T and NK92 ACDVs to cancer cells possessing the xenoantigen, N-glycolyl neuraminic acid GM3 ganglioside, using the 14f7hT antibody or the tumour antigen, epidermal growth factor receptor, using the nimotuzumab antibody...14F7hT-conjugated NK92 ACDVs showed cytotoxic activity against chronic lymphocytic leukaemia biopsies. This research shows the potential for using antibody-conjugated, cytotoxic T and NK ACDVs as a feasible and effective approach for tumour-targeted immunotherapy.

Upon external validation, the genes GZMK, GZMA, ITGAL, and IL7R were modifiable with ICI and associated with improved overall survival. Further investigation is needed to assess if patients with low baseline expression of these genes may benefit from ICI around the time of surgery.

Our findings provide new insights into the metabolic and immunological mechanisms underlying SOC, and highlight potential targets for therapeutic interventions.

Furthermore, the antimigratory effect of 6-mercaptopurine was reversed by TFF3 overexpression, confirming the functional specificity of this drug-target interaction. Notably, tumors with high TFF3 expression (TFF3hi) exhibited elevated resistance to PD-1 inhibitors but heightened sensitivity to MAPK inhibitors, suggesting a potential theranostic framework for ALNM stratification.

This discovery suggests a new mechanism for TCR involvement in irAE myocarditis, focusing on T cell activation through the TCR's functional promiscuity, which relies more on TCR-MHC interactions than on specific peptide features. Overall, this research provides a foundation for new strategies targeting TCR physical properties to reduce risks and develop more precise therapies for vulnerable patients.

These outcomes provide an efficient ferroptosis-related gene-based diagnostic model for CRC. Nevertheless, before its use in real-time settings, more clinical studies are required to confirm its diagnostic value.

This process augments the antitumor immunity of NK cells while concurrently enhancing their antibacterial function, leading to intensified clearance of Fn and further alleviation of immunosuppression, thereby creating a positive feedback loop. The LYC@Bac biohybrid offers a precise strategy to modulate intratumoral microbiome-immune cell interactions, providing a promising approach for enhanced cancer immunotherapy.

It enables robust detection of GzmA in vitro and in cells, with an excellent signal-to-noise ratio. These activatable probes will support downstream activity-based protein profiling and enable noninvasive imaging of the enzyme activity, offering a powerful means for dissecting the multifaceted biology of GzmA within the tumor immune microenvironment.

Importantly, NKG2A blockade enhanced bacterial clearance in PBMCs from TB patients. These findings identify NKG2A as a key immune checkpoint mediating cytotoxic dysfunction in TB and support its blockade as a strategy to restore the host antimicrobial response.

Our study provides novel insights into the molecular properties of residual malignant clones within MAR that appear silenced, surrounded by a putatively anti-tumor immune response.

In vivo, the knockdown of PSMD11 promoted the anti-tumor effect of anti-PD-1 therapy. This study showed that PSMD11 recruits USP14 to modulate the deubiquitinating degradation of PD-L1 to promote immune escape in NSCLC.